Abstract
The prognosis of patients with platinum-refractory head and neck squamous cell carcinoma (HNSCC) was poor. Sintilimab is an immune checkpoint inhibitor. Nab-paclitaxel is a nanoparticle taxane that showed activity in platin-resistant HNSCC. This study aimed to evaluate the efficacy and safety of sintilimab plus nab-paclitaxel in patients with platinum-refractory HNSCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
